Pure Global

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers - Trial NCT06399315

Access comprehensive clinical trial information for NCT06399315 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eilean Therapeutics and is currently Recruiting. The study focuses on AML. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06399315
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06399315
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

Study Focus

AML

ZE46-0134 or placebo

Interventional

drug

Sponsor & Location

Eilean Therapeutics

Perth, Australia

Timeline & Enrollment

Phase 1

Jul 28, 2023

Nov 01, 2024

64 participants

Primary Outcome

Plasma concentration

Summary

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of
 ZE46-0134 efficacy in Healthy Volunteers after single and multiple daily doses of the study
 drug

ICD-10 Classifications

Acute myeloblastic leukaemia [AML]

Data Source

ClinicalTrials.gov

NCT06399315

Non-Device Trial